หน้าแรก
ค้นหา
Dr. Verma Discusses Biosimilars for Trastuzumab
No description available
แสดงข้อมูลเพิ่มเติม 1
Dr. Verma Discusses Biosimilars for Trastuzumab
Dr. Verma Discusses Biosimilars in the Oncology Sphere
Dr. Verma Discusses Challenges With Biosimilars in Oncology
Trial of proposed trastuzumab biosimilar, MYL-1401O vs herceptin
Biosimilar Trastuzumab
Dr. Verma on Immunotherapy in HER2+ Breast Cancer
Dr. Verma on Incorporating Biosimilars into Practice
Mylan biosimilar as good as Herceptin in advanced breast cancer
The use of trastuzumab and biosimilars in the treatment of breast cancer
Dr. Dang on the Significance of the MYL-1401O Biosimilar in HER2-Positive Metastatic Breast cancer
Dr. Markman on the Concept of Biosimilars in Oncology
The Future Direction of Biosimilars
Dr. Somer on the Expansion of Biosimilars in Oncology
Successful implementation of biosimilars through effective communication
Dr. Hamilton on the Impact of Biosimilars in Oncology
Dr. Slamon Discusses the Future of Biosimilars in Oncology
Dr. Brufsky Discusses Reasons to Use Biosimilars in Oncology
Dr. Preeshagul on Education for Biosimilars in Oncology
Dr. Cuellar on Concerns With Extrapolating Data for Biosimilars
Dr. Schwartzberg on Increasing Competition With Biosimilars in Oncology
